GA-BIOLOG-ID
23.7.2020 14:02:04 CEST | Business Wire | Press release
Biolog-id, LLC, a world leader in connected solutions for blood products, and South Texas Blood & Tissue Center, a leading provider of blood products throughout South Texas and beyond, mark three months of successful utilization of Biolog-id’s dedicated Convalescent Plasma solution in its supply chain. The deployed solution provides real-time visibility to convalescent plasma from collection to distribution, streamlining inventory, improving efficiency, and ultimately maximizing Return on Donation. Better visibility to the inventory facilitates efficient management of convalescent plasma, and so increases the availability of these scarce and valuable antibodies to the COVID-19 patients who need them.
“It was key for our team to ensure that Biolog-id’s solution could adapt to rapid changes in manufacturing, regulation, and market conditions for this unique product category,” said Elizabeth Waltman, Chief Operating Officer at South Texas Blood & Tissue Center. “Three months later we can fully appreciate how important that flexibility was for our blood center and for the COVID-19 patients that rely on us.”
“In addressing the need for a Convalescent Plasma solution, we used an inside-the-box approach to innovation,” said Amit Mayer, VP Innovation & Analytics at Biolog-id LLC. “This allowed us to leverage existing elements of our hardware, software, and industry know-how to rapidly develop a robust solution for a completely new type of blood product.”
“Our culture of collaboration meshed well with the needs of South Texas Blood & Tissue Center and their desire to positively influence patient outcomes.,” said Troy L. Hilsenroth, CEO Biolog-id LLC. “The solution we have deployed demonstrates our joint commitment to find new and better ways to track, store, and distribute high-value products in healthcare.”
About Biolog-id
Biolog-id has developed a patented smart solution for the management and traceability of sensitive, high-value health products throughout the hospital supply chain to ensure safe delivery from donor to patient. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has 90 employees worldwide. Biolog-id is owned by its founder, managers, and the Xerys Funds.
Company URL : www.biolog-id.com
About South Texas Blood & Tissue Center
The South Texas Blood & Tissue Center (STBTC) is a nonprofit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties. It is the largest blood supplier in the region. In addition, it recovers and distributes donated human tissue for transplant. STBTC has a 45-year history serving the South Texas community. It is part of the BioBridge Global
family of nonprofit organizations, which offers services in regenerative medicine and research including blood banking and resource management; cellular therapy; umbilical cord blood collection and storage; donated human tissue recovery and distribution for transplant; and testing of blood and plasma products to help patients in the United States and worldwide. STBTC has seven donor rooms in South Texas and conducts hundreds of mobile blood drives each year. STBTC is online at SouthTexasBlood.org
.
Company URL: www.southtexasblood.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005067/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom